Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma

Table 5 Percentage distribution (weighted for the sampling fraction) of chemotherapy agents by selected therapeutic combinations gastroesophageal adenocarcinoma patients diagnosed in 2001; NCI: Patterns of care study (n = 1356)¹ (Wt%)

	Lower esophagus		Gastric-cardia		Stomach
	I-III	IV-V	I-III	IV-V	I-III	IV-V
Chemotherapy only
Etoposide + Doxorubicin + Cisplatin	1 patient	0	0	0	0	0.6
5-FU only	0	3.2	0	3.3	15.9	5.1
Mitomycin only	0	16.7	0	0	0	0
Paclitaxel only	0	2.1	19.2	3.3	0	0
Capcitabine only	0	0	0	0	0	4.4
Gemcitabine only	0	0	0	3.1	0	1.2
5-FU + 1 agent	0	18	56	16.6	25.5	18.8
5-FU + 2 agents	0	4	24.8	40	26.6	23.3
5-FU + 3 agents	0	0	0	7.9	0	15.6
5-FU + 4 agents	0	0	0	2.6	0	2.2
Irinotecan + Paclitaxel	0	20.6	0	1.2	0	0.6
Irinotecan + Cisplatin	0	15.4	0	1.7	0	8.4
Irinotecan + Cisplatin + Paclitaxel	0	0	0	0	20.4	0
Other	0	20	0	20	11.7	19.7
Radiation and chemotherapy
5-FU only	2.1	9.2	34.8	29.2	5.6	20.6
Cisplatin only	0	17.1	0	3.3	0	0
5-FU + Leucovorin	0	1.2	0	0	0	14.3
5-FU + Cisplatin	50.6	28	61.5	32.6	7.9	0
5-FU + Mitomycin	25.1	0.7	0	0	0	0
5-FU + Irinotecan	0	0	0	0	30.1	0
Paclitaxel + Carboplatin	0	13.6	0	4.7	0	0
Chemo, NOS	4.6	8.9	0	7.5	20	13.1
Other	17.6	21.3	3.7	22.7	36.4	52
Surgery, radiation & chemotherapy
5-FU only	5	0	9.4	0	32.4	26.5
5-FU + Leucovorin	13.3	0	17.6	31.7	46.5	40.9
5-FU + Cisplatin	41.1	15.6	27.7	7.3	2.3	0
5-FU + Paclitaxel + Carboplatin	15.3	44.6	1.6	0	0.7	0
Other agents/Combos	25.3	39.8	43.7	61	18.1	32.6

¹13 American Indians/ Native Americans excluded;

NOS: Not otherwise specified.